Resolution criteria

GRCE stock price on November 21, 2025 must close at $3.18 or higher (representing a >6% gain from the $3.00 closing price as of November 17, 2025). Resolution will be determined by checking the closing price on November 21, 2025 via Yahoo Finance GRCE or NASDAQ GRCE. The market resolves YES if the closing price exceeds $3.18, NO otherwise. If the market does not open or close on November 21, 2025, the market resolves N/A.

Background

Grace Therapeutics will present Phase 3 STRIVE-ON safety trial results for GTx-104 at the Society of Vascular and Interventional Neurology annual meeting on November 21, 2025 at 10:55 AM. The trial met its primary endpoint with a 19% reduction in clinically significant hypotension compared to oral nimodipine (28% versus 35%), and 54% of patients had relative dose intensity of 95% or higher compared to only 8% on oral nimodipine, with 29% more patients having favorable functional outcomes at 90 days. Grace Therapeutics has submitted an NDA to the FDA for GTx-104, a novel injectable formulation of nimodipine for treating aneurysmal Subarachnoid Hemorrhage (aSAH), supported by successful Phase 3 STRIVE-ON safety trial results. The FDA has set a PDUFA target date of April 23, 2026 for review.

Considerations

Although STRIVE-ON was not designed or powered to demonstrate efficacy, the trial data have already been presented at the Neurocritical Care Society meeting in September 2025 and were well-received. The November 21 presentation at SVIN is a secondary presentation of the same data, which may limit the novelty impact on stock price.